Pfizer Reports Lung Cancer Development In Some Exubera Users
Executive Summary
Primary lung malignancies have developed in several patients taking Pfizer's inhaled insulin Exubera, which it stopped marketing last fall, but the relationship between the adverse event and the drug remains unclear
You may also be interested in...
MannKind’s Long, Winding Development Road Ends In Approval Of Afrezza Inhaled Insulin
Firm now faces the commercial gauntlet of establishing an inhaled insulin in the crowded diabetes market.
Ghosts of Exubera Haunt Afrezza As Lung Function, Cancer Concerns Weigh Heavily
FDA advisory committee review of MannKind’s inhaled insulin revisits safety issues that troubled Pfizer’s first-of-its-kind product, including a potential lung cancer risk and declines in pulmonary function.
As Pfizer Closes Door On Exubera, Has Window Opened For Others?
Pfizer's decision to terminate its Exubera program - the first inhaled insulin product to hit the market - could provide an opportunity for other drug makers looking to step into the market, especially those prepared to address obstacles illuminated by Pfizer